Liposomes Patents (Class 424/450)
  • Patent number: 10653796
    Abstract: The present invention relates to liposomal compositions, comprising liposomes comprising tetraether lipids (TELs) and cell penetrating peptides (CPPs), wherein said CPPs are attached to a compound being part of the liposome's lipid double layer. The present invention further relates to uses thereof for the oral delivery of therapeutic and/or diagnostic agents.
    Type: Grant
    Filed: October 11, 2016
    Date of Patent: May 19, 2020
    Assignee: Universität Heidelberg
    Inventors: Philipp Uhl, Max Sauter, Uwe Haberkorn, Walter Mier, Gert Fricker
  • Patent number: 10653757
    Abstract: The invention features a method of vaccinating a mammal against Staphylococcus aureus which includes the steps of: a) identifying a mammal at risk for the development of a Staphylococcus aureus skin or soft tissue infection; and b) administering to said mammal an immunogenic amount of a vaccine that includes a polypeptide including an isolated agglutinin-like sequence (Als) 3 protein (Als3p), or an immunogenic fragment thereof, in a pharmaceutically acceptable medium.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: May 19, 2020
    Assignees: NovaDigm Therapeutics, Inc., Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
    Inventors: Michael R. Yeaman, John E. Edwards, Jr., Scott G. Filler, Ashraf S. Ibrahim, Yue Fu, John P. Hennessey, Jr.
  • Patent number: 10646504
    Abstract: Disclosed herein are pharmaceutical compositions that comprise “blends” of lipid nanoparticles and related methods of using such blended compositions to deliver polynucleotides to one or more target cells, tissues or organs. The blended compositions are generally characterized as being able to efficiently deliver polynucleotides to target cells and by their ability to enhance the expression of such polynucleotides and the production of functional proteins by target cells.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: May 12, 2020
    Assignee: Translate Bio, Inc.
    Inventors: Frank DeRosa, Lianne Smith, Michael Heartlein, Braydon Charles Guild
  • Patent number: 10647785
    Abstract: The invention provides highly concentrated chitosan-nucleic acid polyplex compositions and dispersions, and methods for producing the compositions and dispersions. Methods of mixing the chitosan-nucleic acid polyplexes include an inline mixing of chitosan solution and nucleic acid solution, followed by further concentrating the dispersion of chitosan-nucleic acid polyplexes, optionally with an aggregation inhibitor. Further provides are methods for altering the diameter of chitosan-nucleic acid polyplexes.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: May 12, 2020
    Assignee: ENGENE, INC.
    Inventors: Eric Hsu, Carlos Fleet, Anthony Cheung, Jun Gao
  • Patent number: 10647968
    Abstract: The present invention discloses a new anti-tumor medicament comprising a mutant of endostatin. The mutant comprises a mutation in the ATP-binding site of endostatin and has a decreased ATPase activity and an increased anti-angiogenesis activity.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: May 12, 2020
    Assignees: Tsinghua University, Beijing Protgen Ltd.
    Inventors: Yongzhang Luo, Peng Liu, Xinan Lu, Yang Chen, Yan Fu, Guodong Chang, Daifu Zhou
  • Patent number: 10639304
    Abstract: The disclosed molecules are inhibitors of Bcr-Abl and Src kinases. The molecules are cytotoxic to Gleevec resistant cells. Inhibitors of Bcr-Abl and Src kinases are used in the treatment of Chronic Myelogenous Leukemia among other diseases.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: May 5, 2020
    Inventor: Ayyappan K. Rajasekaran
  • Patent number: 10639278
    Abstract: Metastable liposomal formulations for hydrophobic drug delivery to a tissue or tissue lumen such the bladder have been developed. These are at least one micron in diameter and formed of one or more lipids having entrapped in the lipid a hydrophobic therapeutic, prophylactic or diagnostic agent. The greater stability of these liposomes, as well as the enhanced transfer of entrapped agent into the adjacent tissue, provides for better delivery, especially of hydrophobic agents such as tacrolimus which does not penetrate tissue well. The metastable liposomal formulations can be administered locally, preferably by instillation, or topically, for example, by spraying or painting, to a tissue or tissue lumen such as the bladder in need of treatment.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: May 5, 2020
    Assignee: Lipella Pharmaceuticals, Inc.
    Inventors: Jonathan H. Kaufman, Michael B. Chancellor
  • Patent number: 10632072
    Abstract: The present disclosure provides systems and methods for the continuous production of liposomes. An example method includes (a) mixing a solution of lipid and organic solvent from one or more containers to create an organic solvent-lipid solution, (b) providing the organic solvent-lipid solution to a first inlet of an injection port at a first flow rate, wherein the first inlet is in fluid communication with a first conduit, (c) providing an aqueous solution to a second inlet of the injection port at a second flow rate, wherein the second inlet is influid communication with a second conduit, wherein the first conduit is positioned concentrically within the second conduit at an outlet of the injection port, and wherein the first conduit extends through the outlet of the injection port, and (d) mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: April 28, 2020
    Assignee: University of Connecticut
    Inventors: Antonio Costa, Diane J. Burgess
  • Patent number: 10634685
    Abstract: Disclosed is a new and emerging serotype of Streptococcus pneumoniae designated serotype 6C, and assays and monoclonal antibodies useful in identifying same. Also disclosed is a novel pneumococcal polysaccharide with the repeating unit {?2) glucose 1 (1?3) glucose 2 (1?3) rhamnose (1?3) ribitol (5?phosphate}. This new serotype may be included in pneumococcal vaccines.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: April 28, 2020
    Assignees: The UAB Research Foundation, Fundacao Oswaldo Cruz
    Inventors: Moon H. Nahm, Jisheng Lin, Angela P. Brandao, Maria Cristina Brandileone
  • Patent number: 10633681
    Abstract: The present invention provides an apparatus and methods for producing tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) and cannabichromenic acid (CBCA) in different ratios. The apparatus comprises: (i) a bioreactor comprising (a) an automated supply system configured to deliver a first automated supply of cannabigerolic acid (CBGA), a cannabinoid acid synthase, and a reaction mixture; and (b) a second automated system to cease the reaction; (ii) a controller configured to modify a property of the reaction mixture to produce the desired products; and (iii) an extractor configured to recover the tetrahydrocannabinolic acid (THCA), cannabichromenic acid (CBCA) or cannabidiolic acid (CBDA) and cannabichromenic acid.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 28, 2020
    Assignee: Teewinot Technologies Limited
    Inventors: Robert Winnicki, Marc Donsky, Mingyang Sun, Richard Peet
  • Patent number: 10627364
    Abstract: Method for interfacing an integrated circuit with a biological ion channel, the integrated circuit being at least partially disposed within an electrolytic solution and including an amplifier and one or more electrodes on a surface thereof, includes forming one or more microwells proximate the one or more electrodes, applying a lipid membrane over the integrated circuit proximate the microwells, and placing a further electrode in the electrolytic solution proximate the lipid membrane on a side opposite the integrated circuit. A biological ion channel interface is also provided.
    Type: Grant
    Filed: October 8, 2014
    Date of Patent: April 21, 2020
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Kenneth L. Shepard, Jacob Rosenstein, Siddharth Ramakrishnan, Jared Roseman
  • Patent number: 10624850
    Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 21, 2020
    Assignee: Heron Therapeutics, Inc.
    Inventors: Thomas B. Ottoboni, Han Han
  • Patent number: 10624852
    Abstract: Provided herein are methods and compositions for the delivery of bioactive compounds to a cell, tissue, or physiological site. The compositions comprise delivery system complexes comprising liposomes encapsulating a biodegradable ionic precipitate having incorporated therein a bioactive compound and delivery system complexes comprising a biodegradable ionic precipitate ionically bound to a surrounding lipid bilayer, wherein the biodegradable ionic precipitate comprises a bioactive compound. Also provided herein are methods for the treatment of a disease or an unwanted condition in a subject, wherein the methods comprise administering the delivery system complexes comprising bioactive compounds that have therapeutic activity against the disease or unwanted condition to the subject.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: April 21, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Leaf Huang, Jun Li
  • Patent number: 10617672
    Abstract: A composition comprising liposomes comprising a lipid layer defining an internal aqueous compartment, an anthracycline drug entrapped in the internal aqueous phase and mitomycin C prodrug incorporated into the lipid layer is described.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: April 14, 2020
    Assignees: Lipomedix Pharmaceuticals Ltd., Shaare Zedek Scientific Ltd.
    Inventors: Alberto Gabizon, Patricia Ohana, Hilary Shmeeda
  • Patent number: 10617642
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: April 14, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
  • Patent number: 10617682
    Abstract: Embodiments relate to compositions comprising a prochlorperazine compound and a nasal carrier, including methods for formulating such compositions for pharmaceutical applications, for example, for treating or reducing the incidence of migraine headaches. Additional embodiments relate to articles comprising a prochlorperazine compound and a nasal carrier, including use of such articles as nasal drops or nasal sprays. Further embodiments relate to methods for using such articles, for example, for treating or reducing the incidence of migraines.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: April 14, 2020
    Assignee: Roseman University of Health Sciences
    Inventor: Venkata Kashyap Yellepeddi
  • Patent number: 10610496
    Abstract: The present invention provides a pharmaceutical composition for reducing localized fat, comprising drug-containing micelles made of surfactants, and curcumin encapsulated in said drug-containing micelles. This pharmaceutical composition for reducing localized fat can reduce the fat at the administration site, and has the advantages of high stability, high bioavailability for fat tissue, few side effects, and sustained release.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: April 7, 2020
    Assignee: CALIWAY BIOPHARMACEUTICALS CO., LTD.
    Inventor: Yu-Fang Ling
  • Patent number: 10610486
    Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.
    Type: Grant
    Filed: October 27, 2011
    Date of Patent: April 7, 2020
    Assignee: Pacira Pharmaceuticals, Inc.
    Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
  • Patent number: 10596114
    Abstract: The present invention is directed to a liposome composition for use in the peritoneal dialysis of patients suffering from endogenous or exogenous toxicopathies, wherein the pH within the liposomes differs from the pH in the intraperitoneal cavity and wherein the pH within the liposome results in a liposome-encapsulated charged toxin. The invention also relates to a pharmaceutical composition comprising said liposomes. A further aspect of the present invention relates to a method of treating patients suffering from endogenous or exogenous toxicopathies, preferably selected from drug, metabolite, pesticide, insecticide, toxin, and chemical warfare toxicopathies, more preferably hyperammonemia, comprising the step of administering liposomes of the invention in a therapeutically effective amount into the peritoneal space of a patient in need thereof. Next to human, the present invention is particularly suitable to veterinary aspects.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: March 24, 2020
    Assignee: ETH ZURICH
    Inventors: Jean-Christophe Leroux, Vincent Forster
  • Patent number: 10596115
    Abstract: A method for prevention and/or treatment of diminution of bone tissue using a composition comprising a compound selected from Withaferin A (WFA), Withanolide A, and Withanone. The composition showed enhanced WFA bioavailability in rodents against plain WFA, promotes bone marrow cell differentiation, and increases the percent of bone volume to tissue volume (BV/TV %) by 3 folds as compared to free Withaferin A (WFA).
    Type: Grant
    Filed: July 16, 2014
    Date of Patent: March 24, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Ritu Trivedi, Prabhat Ranjan Mishra, Divya Singh, Vikram Khedgikar, Priyanka Kushwaha, Sulekha Adhikary, Dharmendra Choudhary, Jyoti Gautam, Avinash Kumar, Anirudha Karvande, Ashwni Verma, Shweta Sharma, Prabodh K Trivedi, Neelam S. Sangwan, Rajender S. Sangwan
  • Patent number: 10596123
    Abstract: A method of delivering exosomes and other micro vesicles to a biological target includes the steps of 1) providing blood, (2) separating plasma from the provided blood, and (3) separating the solution with the exosomes therefrom, (4) encapsulating the exosomes, and (5) delivering the exosomes. The step of encapsulation may be accomplished by water bead process, alginate bead process, spray drying bead formation, or plating. The biological target may be a human or animal heart, bone/joint, wound or skin. A method of encapsulating an exosome, a method of using an encapsulated exosome, compositions including encapsulated exosomes, and an encapsulated exosome per se are also disclosed.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: March 24, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Atta Behfar, Andre Terzic, William Cook, Ruben Crespo
  • Patent number: 10596213
    Abstract: Methods of improving mammalian carbohydrate metabolism and treating, preventing, or halting the progression of type 2 diabetes mellitus involve the consumption of a nutritional composition containing fruit or vegetable pomace. The pomace is produced from native plant tissue and contains a mixture of soluble and insoluble fiber. Periodic consumption of the composition normalizes blood glucose concentration and controls body weight.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: March 24, 2020
    Assignee: Brandeis University
    Inventors: Kenneth C. Hayes, Daniel Perlman
  • Patent number: 10588961
    Abstract: The present application relates to novel administration regimens for poxviral vectors comprising nucleic acid constructs encoding antigenic proteins and invariant chains. In particular the use of said poxviral vectors for priming or for boosting an immune response is disclosed.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: March 17, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Stefano Colloca, Riccardo Cortese, Antonella Folgori, Alfredo Nicosia
  • Patent number: 10588896
    Abstract: The invention relates to pyridine-3,5-bis-thiocyanates which are new active substances for the treatment and prevention of retroviral infections and secondary diseases thereof, in particular HIV infections and AIDS, from the group of deubiquitinase inhibitors. Administration of the compounds of the invention increases the immunogenicity of viral proteins and thus the antiviral response.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: March 17, 2020
    Assignee: IMMUNOLOGIK GMBH
    Inventors: Ulrich Schubert, Christian Setz, Wolfgang Brysch, Jörg Von Wegerer
  • Patent number: 10590417
    Abstract: Disclosed herein are compositions comprising extracellular vesicles, such as exosomes, displaying an RNA nanoparticle on its surface. The RNA nanoparticle can target the extracellular vesicle to a given cell via a targeting moiety. The extracellular vesicle can also comprise a functional moiety, which can be used in treatment or diagnostics.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: March 17, 2020
    Assignee: Ohio State Innovation Foundation
    Inventors: Peixuan Guo, Fengmei Pi, Hui Li, Shaoying Wang
  • Patent number: 10588871
    Abstract: Described herein are transdermal formulations of phytocannabinoids and methods of using the same in the treatment of pain and/or inflammation.
    Type: Grant
    Filed: June 28, 2019
    Date of Patent: March 17, 2020
    Assignee: NEXZOL PHARMA, INC.
    Inventors: Joseph M. Fracassi, Thomas J. Scarlata
  • Patent number: 10583101
    Abstract: The present invention relates to a pharmaceutical lipid composition comprising nitrosoureas and process for its preparation. In particular, the compositions of present invention are useful in the treatment of brain cancers having improved physicochemical and pharmacokinetic characteristics.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: March 10, 2020
    Assignee: EMCURE PHARMACEUTICALS LIMITED
    Inventors: Deepak Pragjibhai Gondaliya, Hiren Pravinbhai Patel, Arpan Suresh Chudasama, Neha Manubhai Patel, Mukund Keshav Gurjar
  • Patent number: 10583104
    Abstract: Compositions and methods for therapeutic delivery are disclosed. More particularly, the present disclosure relates to nanoparticle compositions that sequester the activity of a target molecule while leaving other domains accessible to bind targeted tissues of interest. Methods for thrombus dissolution include administering a nanoparticle reversibly coupled to a target molecule that can dissolve a blood clot. Compositions and methods for inducing blood clotting are also disclosed. Methods for inducing blood clotting include administering a nanoparticle reversibly coupled to a target molecule that can induce the formation of a blood clot. Methods for sequestering a target molecule are also disclosed. The method includes reversibly coupling a target molecule to a nanoparticle having an affinity ligand that reversibly couples the target molecule, and thus, sequesters the target molecule activity until the target molecule interacts with its substrate resulting in the release of the target molecule.
    Type: Grant
    Filed: August 4, 2015
    Date of Patent: March 10, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Jeffrey A. Kline, Nathan J. Alves, Daren M. Beam
  • Patent number: 10583098
    Abstract: CoQlO has a stimulatory effect on fibroblasts and keratinocytes, increases ATP production, decreases pain. The formulations are useful for promoting acute wound healing, fatigue and treatment of acute and chronic pain.
    Type: Grant
    Filed: May 2, 2007
    Date of Patent: March 10, 2020
    Inventors: Sung Lan Hsia, Niven Rajin Narain, Indushekhar Persaud
  • Patent number: 10583118
    Abstract: The present invention refers to the use of N-acetyl-5-methoxytryptamine (melatonin) and/or an analogue thereof, for use in the medical or veterinary field in the assisted reproduction for promoting the mechanism of implantation of the embryo, and in particular for the prevention of implantation failure into the uterus, by topical administration of an effective amount in a mammalian subject female in need of such treatment, and related compositions, culture media and medical devices.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: March 10, 2020
    Assignee: Ares Trading S.A.
    Inventor: Nicoletta Maxia
  • Patent number: 10568815
    Abstract: The present invention relates to a composition, especially a cosmetic composition, for caring for and/or making up keratin materials, comprising at least: a non-aqueous medium containing at least one hydrocarbon-based oil, particles of at least one polymer that is surface-stabilized with a stabilizer, the polymer of the particles being a C1-C4 alkyl (meth) acrylate polymer; the stabilizer being an isobornyl (meth)acrylate polymer chosen from isobornyl (meth)acrylate homopolymer and statistical copolymers of isobornyl (meth)acrylate and of C1-C4 alkyl (meth)acrylate present in an isobornyl (meth)acrylate/C1-C4 alkyl (meth)acrylate weight ratio of greater than 4; and a hydrophobic film-forming polymer chosen from block ethylenic copolymers and hydrocarbon-based resins, and. mixtures thereof.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 25, 2020
    Assignee: L'OREAL
    Inventors: Philippe Ilekti, Laure Daubersies, Nathalie Gavache, Stephane Douezan
  • Patent number: 10568849
    Abstract: A method for preventing, treating, or ameliorating a microbial infection can include administering thymoquinone or a pharmaceutical composition comprising thymoquinone to a patient in need thereof. The patient may be suffering from a microbial infection caused by gram-negative bacteria, gram-positive bacteria, or fungi. The microbial infection may be caused by gram negative bacteria. The gram-negative bacteria may include Acinetobacter baumannii. The gram-negative bacteria may include Pseudomonas aeruginosa. The microbial infection may be caused by antimicrobial sensitive Acinetobacter baumannii or antimicrobial resistant Acinetobacter baumannii.
    Type: Grant
    Filed: November 7, 2018
    Date of Patent: February 25, 2020
    Assignee: King Saud University
    Inventors: Fahad Ibrahim Al-Jenoobi, Mohd Aftab Alam, Mohamed Hamed Al-Agamy
  • Patent number: 10562849
    Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: February 18, 2020
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Daniel J. Siegwart, Jason B. Miller
  • Patent number: 10561610
    Abstract: The present invention provides a hybrid biocompatible carrier (hybridosome) which comprises structural and bioactive elements originating from at least one biocompatible delivery module (BDM) and at least one engineered drug encapsulation module (EDEM) comprising at least one tunable fusogenic moiety. The invention further provides pharmaceutical compositions comprising said hybridosomes, processes for their manufacture, as well as pharmaceutical uses and pharmaceutical methods based thereon.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: February 18, 2020
    Assignee: ANJARIUM BIOSCIENCES AG
    Inventor: Joel De Beer
  • Patent number: 10561642
    Abstract: The present invention concerns the use of castanospermine or other alpha-glucosidase inhibitors for the treatment or prevention of Zika virus infections. Aspects of the invention include methods for treating or preventing Zika virus infection by administering an alpha-glucosidase inhibitor (e.g., an alpha-glucosidase I inhibitor) to a subject in need thereof; methods for inhibiting a Zika virus infection in a cell in vitro or in vivo; pharmaceutical compositions; packaged dosage formulations; and kits for treating or preventing Zika virus infection.
    Type: Grant
    Filed: December 28, 2017
    Date of Patent: February 18, 2020
    Assignee: FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    Inventors: Eric Holmes, Gary Ostrander
  • Patent number: 10556875
    Abstract: A series of double-component, bis O2-aryl diazeniumdiolate derivatives are provided, of which each molecule can release up to four nitric oxide molecules. These compounds show cytotoxic activities to cancer cells, such as human leukemia, breast cancer and lung cancer. Among them, the compound 3 showed the highest specific activity against human leukemia cells.
    Type: Grant
    Filed: October 9, 2018
    Date of Patent: February 11, 2020
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventor: Shengxi Chen
  • Patent number: 10555907
    Abstract: Described are controlled-release solid dosage forms of mesalamine. In one aspect of the invention the controlled-released solid dosage forms of mesalamine are capsules comprising a plurality of coated mini-tablets. Another aspect of the invention related to a methods of treating a patient suffering from inflammatory bowel disease, comprising the step of administering to the patient a therapeutically effective amount of the solid dosage form. The invention also relates to methods of inducing remission of inflammatory bowl disease and maintaining remission of inflammatory bowel disease. In certain aspects, the inflammatory bowel disease is ulcerative colitis or Crohn's disease.
    Type: Grant
    Filed: August 31, 2018
    Date of Patent: February 11, 2020
    Assignee: Santarus, Inc.
    Inventors: Craig Michael Bowe, John Christopher Carter, Dana Elaine Moseson, Stephen Paul Levine
  • Patent number: 10556861
    Abstract: What is described is a compound of formula III or IV wherein R1 is a branched alkyl with 12 to 20 carbons; R2 is a linear alkyl with 5 to 10 carbons or a branched alkyl with 12 to 20 carbons; L1 and L2 are each a bond or a linear alkylene having 1 to 3 carbon atoms, when L3 is a bond; L1 and L2 are each a linear alkylene or alkenylene 5 to 18 carbon atoms, when L3 is an alkylene of 5 to 18 carbons; X is S or O; R3 is of a lower alkyl; and R4 and R5 are the same or different, each a lower alkyl; or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: February 11, 2020
    Assignee: Arcturus Therapeutics, Inc.
    Inventors: Joseph E. Payne, Padmanabh Chivukula
  • Patent number: 10556216
    Abstract: Methods and devices for producing a population of liposomes are provided. Aspects of the methods include applying a centrifugal force to a suspension of liposomes in a manner sufficient to pass the liposomes through a porous membrane to produce a population of liposomes. Aspects of the invention further include devices, systems and kits useful for performing the methods.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: February 11, 2020
    Assignee: BECTON, DICKINSON AND COMPANY
    Inventors: Oleg Guryev, Tatyana Chernenko, Marybeth Sharkey
  • Patent number: 10548837
    Abstract: A topical formulation comprising Montelukast or a pharmaceutically acceptable salt thereof, a gelling agent and water for the treatment of atopic dermatitis.
    Type: Grant
    Filed: May 3, 2017
    Date of Patent: February 4, 2020
    Assignee: TARO PHARMACEUTICAL INDUSTRIES LTD.
    Inventors: Avi Avramoff, Helena Shifrin, Irena Oleinik, Ron Schlinger, Tzviel Sheskin, Vered Rosenberger
  • Patent number: 10548908
    Abstract: The present invention is directed to compositions and methods for the prevention or treatment of treatment of heterotopic ossification, vascular calcification, or pathologic calcification.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: February 4, 2020
    Assignee: Nostopharma, LLC
    Inventor: Ekaterina Vert-Wong
  • Patent number: 10548905
    Abstract: Amorphous forms of onapristone and methods of making such amorphous forms are provided. Amorphous forms can be characterized by their X-ray powder diffraction patterns and other properties.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: February 4, 2020
    Assignee: CONTEXT BIOPHARMA INC.
    Inventors: Harry G. Brittain, Stefan Proniuk
  • Patent number: 10543190
    Abstract: This invention relates to a suppository composition comprising cannabinoids. The suppository composition is formulated for easy absorption through mucosal membrane. The suppository as provided herein is useful for administration of cannabinoids in patients with nausea, vomiting, other conditions preventing swallowing, or conditions wherein suppository administration is required. Methods to manufacture the suppository composition are provided. Methods to treat pain, nausea, post-operative ileus and/or inflammatory bowel diseases using the suppository according to this invention are also provided.
    Type: Grant
    Filed: September 5, 2018
    Date of Patent: January 28, 2020
    Assignee: Axim Biotechnologies, Inc.
    Inventors: Lekhram Changoer, George Anastassov
  • Patent number: 10543273
    Abstract: The present invention is directed to compositions and methods targeting tissue resident cells, such as fibroblasts, in a subject harboring conditions or at risk for conditions that would benefit from anti-fibroblastic therapy. The present invention relates to the use of fluorochemical compositions and methods of delivery that result in retention of the fluorochemical composition and any bioactive agent delivered in combination with the fluorochemical composition.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: January 28, 2020
    Inventor: Matthew T. McLeay
  • Patent number: 10538766
    Abstract: This disclosure relates to methods and compositions for managing vascular conditions by targeting microRNA. In certain embodiments, the disclosure relates to antisense, RNA interference, and blocking oligonucleotide therapeutic compositions and uses related thereto.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: January 21, 2020
    Assignees: Emory University, Georgia Tech Research Corporation
    Inventors: Hanjoong Jo, Dongju Son, Wakako Takabe, Sandeep Kumar, Hhaiwei Qiu, Chanwoo Kim
  • Patent number: 10525004
    Abstract: The present invention relates to composition comprising vesicles and associated with the vesicles, a chemical agent, for use in a method of treatment by therapy wherein the chemical agent is delivered trans- and/or intra-epithelially to a human or animal body, wherein the constructs comprise an amphiphilic block copolymer having a hydrophilic and a hydrophobic block. Methods for forming the composition are also provided.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: January 7, 2020
    Assignee: BIOCOMPATIBLES UK LIMITED
    Inventor: Giuseppe Battaglia
  • Patent number: 10525149
    Abstract: Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: January 7, 2020
    Assignee: MediBeacon Inc.
    Inventors: Richard B. Dorshow, Thomas E. Rogers
  • Patent number: 10525053
    Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In a preferred embodiment, a drug is modified to increase its lipophilicity. In some embodiments the modified drug is homogeneously dispersed within spherical microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and/or organic solvent insoluble. The abuse-deterrent composition retards the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: January 7, 2020
    Assignee: Collegium Pharmaceutical, Inc.
    Inventors: Roman V. Rariy, Alison B. Fleming, Jane Hirsh, Alexander M. Klibanov
  • Patent number: 10517963
    Abstract: Provided is a gene delivery including a polymer network formed by binding phenylboronic acid, sugar, and a low-molecular weight branched polymer. The gene delivery may be stably maintained in vivo and efficiently deliver a gene specifically to cancer cells, such that the gene delivery system may be usefully used as a gene delivery system for chemotherapy.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: December 31, 2019
    Assignees: Institute for Basic Science, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Won Jong Kim, Jinhwan Kim
  • Patent number: 10517823
    Abstract: Provided herein are encapsulated liposomes comprising a lipid bilayer, a first polyethylene glycol (PEG) corona, a targeting molecule and a second PEG corona. The second, encapsulating PEG corona can be reversibly linked to the first PEG corona. Also provided are pharmaceutical compositions comprising the encapsulated liposomes and methods of treating a subject with a disease characterized by production of reactive oxygen species (ROS) with the compositions. Also provided are methods of making the encapsulated liposomes disclosed herein.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 31, 2019
    Assignee: VERILY LIFE SCIENCES LLC
    Inventors: Kimberly Kam, Zhan Wang, Stephen Morton, Nicole Peck